China Shineway Pharmaceutical Group Limited (HK:2877)
:2877
Want to see HK:2877 full AI Analyst Report?
2877 Stock Chart & Stats
HK$8.58
HK$0.18(2.26%)
At close: 4:00 PM EST
HK$8.58
HK$0.18(2.26%)
Day’s Range― - ―
52-Week RangeHK$6.96 - HK$10.47
Previous CloseN/A
Volume914.00K
Average Volume (3M)1.29M
Market Cap
HK$7.48B
Enterprise Value-HK$494.67M
Total Cash (Recent Filing)HK$7.57B
Total Debt (Recent Filing)HK$335.05M
Price to Earnings (P/E)6.3
Beta0.52
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.8%
Share Statistics
EPS (TTM)0.49
Shares Outstanding827,000,000
10 Day Avg. Volume1,790,900
30 Day Avg. Volume1,290,900
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)0.72
Price to Sales (P/S)1.91
P/FCF Ratio5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.12
Revenue Forecast (FY)HK$4.11B
Bulls Say, Bears Say
Bulls Say
High And Durable ProfitabilitySustained very high gross and healthy operating/net margins indicate persistent pricing power and efficient production for proprietary medicines. This structure supports long-term cash generation, funding for R&D and dividends, and resilience to moderate demand cycles without leveraging the balance sheet.
Very Conservative Balance SheetExtremely low leverage combined with steady ROE gives strategic flexibility: the company can fund organic R&D, capex, or M&A without refinancing stress. This reduces default risk and preserves capital allocation optionality across multiple market environments over the next several quarters.
Integrated PCM R&D-to-Distribution ModelVertical integration across product development, manufacturing and dual medical/retail channels supports product control, margin retention and faster commercialization. This durable model aids portfolio depth, channel diversification, and repeatable revenue streams versus firms reliant on single channels.
Bears Say
Weakening Revenue TrendSustained top-line contraction reduces operating leverage and risks reversing margin and cash generation gains. If demand for core PCMs continues to shrink, management will face harder choices on pricing, marketing spend, or restructuring that could permanently lower growth potential.
Margin Softening From 2023 PeakAny structural shift causing margin erosion — e.g., pricing pressure, mix changes or higher input costs — would materially reduce free cash flow and reinvestment capacity. The recent easing signals potential competitive or demand-driven pressures that could persist absent product or channel fixes.
Volatile FCF Growth And Data Visibility LimitsWhile FCF is positive, year-to-year volatility and limited metric visibility complicate forecasting and capital planning. This uncertainty raises execution risk for sustained dividend policy, R&D pacing or opportunistic investments over the coming 2–6 months.
China Shineway Pharmaceutical Group Limited News
2877 FAQ
What was China Shineway Pharmaceutical Group Limited’s price range in the past 12 months?
China Shineway Pharmaceutical Group Limited lowest stock price was HK$6.96 and its highest was HK$10.47 in the past 12 months.
What is China Shineway Pharmaceutical Group Limited’s market cap?
China Shineway Pharmaceutical Group Limited’s market cap is HK$7.48B.
When is China Shineway Pharmaceutical Group Limited’s upcoming earnings report date?
China Shineway Pharmaceutical Group Limited’s upcoming earnings report date is Sep 01, 2026 which is in 125 days.
How were China Shineway Pharmaceutical Group Limited’s earnings last quarter?
China Shineway Pharmaceutical Group Limited released its earnings results on Mar 27, 2026. The company reported HK$0.486 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.486.
Is China Shineway Pharmaceutical Group Limited overvalued?
According to Wall Street analysts China Shineway Pharmaceutical Group Limited’s price is currently Overvalued.
Does China Shineway Pharmaceutical Group Limited pay dividends?
China Shineway Pharmaceutical Group Limited pays a Semiannually dividend of HK$0.12 which represents an annual dividend yield of 5.8%. See more information on China Shineway Pharmaceutical Group Limited dividends here
What is China Shineway Pharmaceutical Group Limited’s EPS estimate?
China Shineway Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Shineway Pharmaceutical Group Limited have?
China Shineway Pharmaceutical Group Limited has 827,000,000 shares outstanding.
What happened to China Shineway Pharmaceutical Group Limited’s price movement after its last earnings report?
China Shineway Pharmaceutical Group Limited reported an EPS of HK$0.486 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.481%.
Which hedge fund is a major shareholder of China Shineway Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:2877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Shineway Pharmaceutical Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.07%
12-Months-Change
Fundamentals
Return on Equity
11.90%
Trailing 12-Months
Asset Growth
12.33%
Trailing 12-Months
Company Description
China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People's Republic of China and Hong Kong. The company offers modern Chinese medicines in the form of soft capsules, granules, and injections, as well as TCM Formula Granules in various therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. It also trades in agricultural products. The company was incorporated in 2004 and is headquartered in Shijiazhuang, the People's Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
―
Pak Fah Yeow International Limited
―
Jacobson Pharma Corporation Limited
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―
Options Prices
Currently, No data available
---